Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHAL304 > Cardiovascular > Flashcards

Cardiovascular Flashcards

1
Q

Chronotropy

A

Heart rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Inotropy

A

Force of heart contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Adrenoreceptors

A

a1 - constrict vascular SM, inotropy
a2 - constrict vascular SM, reduce preganglionic NA release
B1 - chronotropy, inotropy, renin secretion (cAMP)
B2 - dilate arterioles, some chronotropy/inotropy (cAMP)
B3 - dilate coronary microvasculature, decrease inotropy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Propanolol

A

Inhibit B1 and B2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Metoprolol

A

B1 selective = no rest effects, decrease rate and force and renin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Carvediol

A

B1, B2, a1 (some vasodilation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Beta blockers activity

A

decrease cardiac output, decrease BP, decrease renal renin output, negative chronotropic (SA and AV nodes), negative inotropic, decrease work, decrease oxygen consumption
metabolised CYP2D6
Improve cardiac CA2+ storage and release via cAMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

B3

A

Nebivolol is agonist and B1 blocker
ARs - cardiomyocyte relaxation, decreased cAMP, eNOS activation -> relaxation of vascular smooth muscle, reduce remodelling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Baroreceptors

A

Detect initial drop in cardiac output with beta blockers, causing an initial increase in peripheral resistance (long term decreases)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Therapeutic uses of beta blockers

A

Hypertension - renin, cardiac output, decrease peripheral resistance (not used for this anymore due to low BP)
rate control - anti arrhythmic
Angina - reduce oxygen consumption
Heart failure - not a great effect, chronotropy, vasodilation
Anxiety - tremors and HR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

beta blockers adverse effects

A

bronchospasm (B2 respiratory inhibition - asthma), withdrawal (taper), heart failure (too slow), low exercise tolerance, peripheral vasoconstriction, heart block (via conduction), CNS effects (cross BBB), worsening lipid profiles (lipoprotein lipase - increase bad cholesterol)
Type 2 diabetes - hypoglycaemia response inhibited

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Atenolol

A

Only bblocker that is hydrophilic, does not cross BBB
Excreted in urine unchanged, longer half life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ischaemic heart disease

A

Interruption of cardiac blood supply involving epicardial coronary vessels, block oxygen to heart. Caused by coronary artery disease (plaque)
Angina to myocardial infarction
chest pain, shortness of breath, exhausted, myocardial wall tissue dies
Treat decreasing ino and chrono, BP, oxygen demand, sympathetic stimulus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Sympathetic effect on adrenergic receptors

A

B1,2 a1 = myocyte death and increased arrhythmias
a1, B1 = vasoconstriction, sodium retention, fibrosis and scarring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Preload and afterload

A

Preload is the filling of the heart and is determined by the wall stretch
Afterload is down stream resistance affecting how the heart squeezes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Carvediol vs 2nd gen B-Blockers

A

Pros - greater drop in BP, no adverse decrease in HR, little impact triglycerides and glucose
Cons - no selectivity, bronchospasm, need twice a day dosing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ACE inhibitor example

A

Cilazapril
Good absorption and bioavailability 60%, half-life 9h, metabolised to active drug by liver, cleared through kidney
Decrease vascular resistance, BP, sodium retention, preload, blood volume return, decrease SM contraction, increase bradykinin vasodilator, downregulates sympathetic activity
AEs - bradykinin = leaky blood vessels, rash, hypotension, swelling of face

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ARB example

A

Candesartan
Prodrug candesartan cilexetil via esterase in GI tract, low bioavailability, half life 9h, CYP2C9 inhibition, excreted in urine (less liver than other ARBs)
Selective to AT1, block all effects of Ang II (not just formation from one thing), no bradykinin accumulation, but lose vasodilator capability, angioedema, renin feedback loop?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Heart failure

A

damage decreases cardiac output and perfusion. Baroreceptors pick up drop and activate the nervous system and noradrenaline. -> salt and water retention, vasoconstriction, ion/chrono

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

RAAS

A

Release of angiotensin II and aldosterone from adrenal cortex
Control sodium excretion and fluid volume plus vascular tone
Liver -> angiotensinogen -> Ang I -> Ang II -> release aldosterone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Angiotension II

A

Vasoconstrictor, smooth muscle proliferator, fluid retention/hypertrophogenic, fibrogenic, apoptosis, NA and aldosterone release, remodelling via AT1 and 2 receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Aldosterone

A

mineralocorticoid receptor agonist
Anti-natriuretic peptide and fibrogenic, salt chloride and water retention, hypertrophy, damage arteries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

RAAS inhibitors

A

Renin inhibitors - stop Ang II formation from angiotenisogen
ACE inhibitors - prevent Ang II from Ang I and bradykinin
AT1 blockers - at receptor (avoid AT2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Renin

A

Released from juxtaglomerular cell on renal afferent arterioles
via stimulation of B1Rs on JG cells, low renal BP, low Na+ conc in distal tubule (glomerulus feedback)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
ACE
Angiotensin converting enzyme Ang I to Ang II Extrinsic (vascular endothelial surface) and intrinsic (in cytosol of tissues)
25
AT1 vs AT2
AT1 - hypertensive effects (vasoconstriction, aldosterone, Na+ reabsorption, cell growth - fibrotic) AT2 - beneficial (vasodilation, decrease BP, inhibit cell growth, anti-fibrotic)
26
Calcium channel blocker drug classes
Dihydropyridines, phenylalkylamines, benzothiazipines
27
Types of voltage gates calcium channels
L-type - long lasting in cardiac and vascular SM T-type - transient in neurons and pacemaker cells
28
Heart conduction
SA node = pacemaker -> AV node = conduction -> cardiomyocytes Via calcium currents, extracellular -> intracellular release
29
Phases of cardiac action potential
Na+ influx -> -> Ca2+ in (L-type) -> K+ out NA/Adr causes CA2+ influx -> slow stroke SA node -> atria -> AV node -> His bundles/Prkinje fibres -> ventricles
30
Calcium channel blockers
Inhibit calcium influx through L-type channels Act on entry into vascular (vasodilation) cardiac (ino) muscle and SA/AV node (chrono)
31
CCB examples
Used in hypertension Dihydropyridine = Amlodipine - vasodilator Phenylalkylamines = Verapamil Benzothiazipines = Diltiazem - depress cardiac contractility, SA/AV nodes (arrhythmias and angina)
32
Amlopidine
vasodilation in arterial smooth muscle, reduce afterload and arterial pressure, stabilises inactive L-type Ca2+ channel state (prevents change to active) selective to arterial due to longer depolarisations in inactive channels Good bioavailablity, peak 6-12h, CYP3A4, plasma bound = 30-50 hour half life ADRs - decrease BP -> tachycardia, increased ino/chrono, increase oxygen demand = not used in angina
33
Varapamil
Binds to open L-type Ca2+ channels (more likely in myocardial cells) suppress cardiac contractility, reduce LTCC recovery from inactivation Decrease oxygen demand (angina), not used in heart failure as may cause heart block or with B-blockers Rapid oral absorption, CYP3A4 inhibiton, lower bioavailability
34
Diltiazem
Cardiac LTCCs and some vascular LTCCs in sarcolemmal membrane of heart and vascular SM -> hypertension, angina (not first line) and arrhythmias Not used in heart failure or with B-blockers, does not cause AV block, hypertension or bradycardia Rapid, 1st pass metabolism, CYP3A4/2D6 and esterases
35
CCB ADRs
Relaxed smooth muscle, facial flushing, constipation, bradycardia, hypotension, AV block, HF
36
Anti-lipidaemics benefits
Dyslipidaemias -> CV disease, endothelial lesions, thrombotic occlusion Hypercholesterolaemia -> coronary heart defects, HTN CV disease + kidney disease cycles -> fucked
37
Cholesterol synthesis
Acetyl coenzyme A -> HMG CoA -reductase> mevalonate (MVA) -> cholesterol In liver and diet, LDL receptors regulate Transported by lipoproteins
38
Types of cholesterol lipoproteins
HDL (picks up used cholesterol), LDL, IDL, VLDL, chylomicrons HDL 2 and 3 = ApoA-I (the rest are ApoB)
39
LDL receptors
Bind apoplipoprotein B100 from LDL -> internalisation of LDL -> recycled receptor, LDL degraded to aas and free cholesterol Cholesterol -> decrease HMG CoA reductase, increase ACAT, decrease LDL Rs
40
Atherosclerosis
Increase in plasma cholesterol, deposition of fatty materials in arteries, low LDLRs, uptake of oxidised LDL by macrophages -> foam cells -> deposition in arteries, calcification, thrombus, occlusion, ulceration
41
Anti hyperlipidaemics
Endogenous Cholesterol Esterase attenuators, LDL receptor degradation inhibitors, exogenous CE uptake inhibitors
42
Endogenous CE attenuators
Statins - atorvastatin Fibrates - bezafibrate Nicotinic acid
43
LDL receptor degration inhibitors
PCSK9 inhibitors - alirovumab
44
Exogenous CE uptake inhibitors
Cholesterol uptake inhibitors - ezetemibe Bile acid binding resins - colestipol and cholestyramine
45
Statins
Atorvastatin Treatment for dylipidaemia Reversible, competitive HMG CoA reductase inhibitors, increase LDLR synthesis, LDL clearance = low LDL in blood, slight HDL increase Pleiotropic = effect on mavalonic acid
46
Atorvastatin
Decrease hepatic cholesterol synthesis Rapid absorption, long half life - 14h, plasma protein binding, poor bioavailability, CYP3A4
47
Pleiotrophy
Inhibit MVA pathway = no isoprenylation = decrease cell growth, increase eNOS, decrease ROS = anti-inflammatory via NFkB
48
Statins adverse effects
myopathy and rhabdomyolysis = release of myoglobin into plasma and kidney Pain from damage to skeletal tissue via mitochondrial function creating ROS? Interact w CYP3A4, 2C9, OATP1B1, glucoronidation
49
Ezetimibe
reduce reuptake of cholesterol from diet into bile
50
Alirocumab
PCSK9 inhibition = decrease LDLR destruction via preventing binding of LDLR 2-4 weeks subcutaneous, 4-6h onset
51
Types of diuretics
Osmotic, loop, thiazide, K+ sparing
52
Kidneys
?
53
Osmotic diuretics
Mannitol Not metabolised = filtered in glomerulus -> pulls water into nephron Causes osmotic stress in proximal tubule lumen limited water reabsorption, sodium retention in urine, draws water out of cells increase extracellular fluid volume (pulmonary oedema and increase renal blood flow) IV for acute emergency, some hypersensitivity reactions
54
Loop diuretics
Frusemide - most potent Organic acid transporter (proximal tubule) -> NKCC2 transporter inhibitor on thick ascending loop (sodium/potassium channel on inner lumen surface) Block sodium influx through NKCC2 to compensate for ATPase activity. Hypertension (decrease BP), oedema, hyperkalaemia, hypercalcaemia
55
Frusimide
4-6h duration, rapid absorption, plasma protein binding, CYP/glucoronidation ADRs - hypovolemia, dizziness, syncope, hyponatraemia, hypokalaemia, Mg2+ and Ca2+ depletion, uric acid retention
56
Thiazide diuretics
Bendroflumathiazide - mild diuretic Inhibit Na+/Cl- transporter (eNCC1) in distal cortical diluting segment = prevent NaCl reabsorption, increase sodium and water excretion Hypertension (decrease BP, peripheral resistance and plasma volume), can be used in renal disease if GFR is maintained
57
Bendroflumathiazide
Oral, 1h onset, variable elimination kinetics, compete w uric acid transporters (OATs), renal elimination Dehydration, alkalosis, uric acid retention, hypokalaemia, dehydration, hyponatremia
58
K+ sparing diuretics
Spironolactone and amiloride At late distal/collecting duct
59
Spironolactone
Aldosterone antagonist at mineralocorticoid receptor (stops promotion of sodium reabsorption and potassium loss via ENaC pump synthesis) First pass metabolism, binds to basolateral surface receptors oral = 70% absorbed, prodrug -> canrenone ADRs - hyperkalemia, GI disturbances
60
Amiloride
ENaC inhibitor, inhibits sodium flux (weak effects on sodium balance) OAT at proximal tubule ADRs - hyperkalaemia Use - drug resistant hypertension, chronic liver failure
61
Antiarrhythmic drugs
Metoprolol, amiodarone, diltiazem, digoxin
62
Arrhythmias
Abnormal rhythm can cause sudden death. Originate in atria/AV node or ventricles Caused by defect in pulse generation via automatic tissue/ectopic beats (tacky/Brady), defect in impulse generation (drops beats) Abnormal depolarisation - Na+ channel effect
63
Classes of antiarrythmics
Class I - interfere with Na+ channel (lignocaine) Class II- B blockers (metoprolol) Class III - decrease potassium efflux (amiodarone) Class Iv - Ca2+ blockers (diltiazem)
64
Class I antiarrythmic
Block fast Na+ channels in use-dependant way -> upstole/phase zero -> plato phase Lignocaine binds to Na+ channels in open and inactivated states, increasing rate and magnitude of depolarisation
65
Class II antiarrythmics
Block NA/A Decrease increasing firing at SA node, slow conductor velocity at AV node Rate control, stress/exercise tachycardias, decrease mortality post-MI Adverse = non-selective, bronchospasm, negative inotropic, fatigue, insomnia, depression
66
Class III antiarrythmics
Block K+ efflux, increase AP duration and refractory period (to repolarisation), decrease Na+, Ca2+ flux Decrease chance of reentry arrythmias, rate control, no pro-arrhythmic action 10-100 day accumulation, can cause pulmonary fibrosis, rashes, thyroid abnormalities
67
Class IV antiarrythmics
Decrease Ca2+ in nodal cells and cardiomyocytes Binds to open state -> promote inactivated channel LTCCs = decrease rate of discharge in SA node, decrease conduction, increase refractory period in AV node and decrease myocardial contraction Don't use with B-blockers
68
Digoxin
Doesn't fit Vaughan Williams classification Increase inotrophy and decrease chronotrophy Cardiac glycoside = inhibit cellular Na+/K+ATPase -> increase inotrophy, decrease sympathetic tone, increase urine, decrease renin release Increase vagal activity of ACh = decrease SA node firing rate, decrease AV conduction velocity, decrease ventricular rate Narrow therapeutic range, oral or IV, lots of interactions, can cause arrhythmias
69
Intravascular thrombi
Can lead to angina, MI, deep vein thrombosis, pulmonary embolism, stroke
70
Prostacyclin (PGI2)
endothelial cells -> inhibit platelet aggregation and secretion, increase cAMP release, decrease COX activity on platelets, decrease prothrombotic trombone production
71
Thrombus formation
Cholesterol -> endothelial boundary -> plaque -> rupture into vessel -> decreased PGI2 synthesis-> thrombin -> release collagen, TXA2, ADP -> platelets can adhere to ECM proteins
72
Thrombin
GPCR agonist -> Ca2+ entry = change platelet shape -> ADP and TXA2 = platelet activation
73
Fibrin
Made from fibrinogen Stabilised platelets, forming polymers in matrix
74
Antiplatelet examples
Aspirin and clipodogrel
75
Anticoagulants examples
LMWH - enoxaparin VKAs - warfarin NOACs - dabigatran
76
Asprin
Broken down in liver to inactive form Inhibit COX irreversibly via acetylation (selective to COX1) Stops COX from forming TXA2 Beneficial for vascular disease Risk = haemorrhage and GI ulceration
77
Clopigodrel
ADP non comp inhibitor on P2Y receptors -> prevent GPIIb/a activation Reduce platelet activation and synergistic with aspirin
78
Warfarin
VitK antagonist, prevent throbs from forming Stop recycling of VitK via epoxide reductase -> can't form prothrombin, factors VII, IX and X CYP2C9/1A2/3A4 - lots of interactions, haemorrhage, GI tract loss, bruising, skin necrosis 1-8h peak, can't measure blood levels have to use international normalised ratio
79
Dabigatran
novel oral anticoagulant
80
Haparin
Bind antithrombin III to inactivate thrombin as well as mediate factor Xa (creates thrombin) Enoxaparin (safer_ Subcutaneous administration, half life 406h, cleared by urine Use to treat deep vein thrombosis

PHAL304 (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions